ATG16L1 rs2241880 和 TP53 rs1042522 与弥漫性大 B 细胞淋巴瘤的特征和病程的关联。
Association of ATG16L1 rs2241880 and TP53 rs1042522 with characteristics and course of diffuse large B-cell lymphoma.
机构信息
Clinic of Hematology, Military Medical Academy, 17 Crnotravska str, 11000 Belgrade, Serbia; MediGroup General Hospital, 3 Milutina Milankovića str, 11070 Belgrade, Serbia.
Clinic of Hematology, Military Medical Academy, 17 Crnotravska str, 11000 Belgrade, Serbia.
出版信息
Pathol Res Pract. 2022 Sep;237:154033. doi: 10.1016/j.prp.2022.154033. Epub 2022 Jul 19.
BACKGROUND
Diffuse large B-cell lymphoma (DLBCL) represents the most frequent lymphoma in adults. Prognosis for DLBCL patients may be evaluated through the most prominent clinical/laboratory parameters or pattern of gene expression. In order to improve prognostic/prediction scores or provide new therapeutic targets, novel genetic markers are needed. This study evaluates the association of ATG16L1 rs2241880 and TP53 rs1042522 with clinical characteristics and course of DLBCL.
METHODS
The study included 108 DLCBL patients treated with R-CHOP. Of these, 44 patients were subjected to stem cell transplantation and 55 to radiotherapy. Genotyping was performed by TaqMan genotyping assays.
RESULTS
Amongst analyzed characteristics and prognostic scores, genotypes were associated with clinical stage (TP53 CG+CC vs GG p = 0.06), extranodal disease (ATG16L1 AG vs AA p = 0.07; AG vs GG p = 0.04), lymphocyte-to-monocyte ratio (LMR) (ATG16L1 AA vs AG+GG, p = 0.052; AA vs GG, p = 0.054) and neutrophils-to-lymphocytes ratio (NLR) (ATG16L1 AA vs AG+GG, p = 0.033; AA vs GG, p = 0.003). Analyzed genotypes didn't impact response to therapy, relapse and therapy-related complications. Considering outcome, patients with ATG16L1 AA had higher survival rate than GG carriers (p = 0.04). In all patients, duration of overall survival (OS) and relapse free survival (RFS) was not affected by analyzed genotypes. When subjected to radiotherapy, patients with ATG16L1 A allele (p = 0.05) or AA genotype (p = 0.03) had superior OS.
CONCLUSION
Our results demonstrated the association of TP53 rs1042522 with clinical stage and ATG16L1 rs2241880 with extranodal disease, LMR and NLR. The impact of ATG16L1 genotypes on OS in patients subjected to radiotherapy, indicates significance of individual single nucleotide polymorphisms (SNPs) in particular subgroups of DLBCL.
背景
弥漫性大 B 细胞淋巴瘤（DLBCL）是成人中最常见的淋巴瘤。DLBCL 患者的预后可以通过最显著的临床/实验室参数或基因表达模式来评估。为了提高预后/预测评分或提供新的治疗靶点，需要新的遗传标志物。本研究评估了 ATG16L1 rs2241880 和 TP53 rs1042522 与 DLBCL 的临床特征和病程的关系。
方法
该研究纳入了 108 例接受 R-CHOP 治疗的 DLBCL 患者。其中，44 例患者接受了干细胞移植，55 例患者接受了放疗。通过 TaqMan 基因分型检测进行基因分型。
结果
在分析的特征和预后评分中，基因型与临床分期（TP53 CG+CC 与 GG，p=0.06）、结外疾病（ATG16L1 AG 与 AA，p=0.07；AG 与 GG，p=0.04）、淋巴细胞与单核细胞比值（LMR）（ATG16L1 AA 与 AG+GG，p=0.052；AA 与 GG，p=0.054）和中性粒细胞与淋巴细胞比值（NLR）（ATG16L1 AA 与 AG+GG，p=0.033；AA 与 GG，p=0.003）有关。分析的基因型并没有影响对治疗的反应、复发和治疗相关的并发症。考虑到结局，ATG16L1 AA 基因型的患者比 GG 携带者有更高的生存率（p=0.04）。在所有患者中，总生存（OS）和无复发生存（RFS）不受分析基因型的影响。当接受放疗时，ATG16L1 等位基因（p=0.05）或 AA 基因型（p=0.03）的患者 OS 更好。
结论
我们的研究结果表明，TP53 rs1042522 与临床分期有关，ATG16L1 rs2241880 与结外疾病、LMR 和 NLR 有关。在接受放疗的患者中，ATG16L1 基因型对 OS 的影响表明，在 DLBCL 的特定亚组中，个体单核苷酸多态性（SNP）的意义。
Zotero 插件